New Adenocarcinoma Research Has Been Reported by a Researcher at Hudson Institute of Medical Research (Phase I/IIa trial in advanced pancreatic ductal adenocarcinoma treated with cytotoxic drug-packaged, EGFR-targeted nanocells and...).

A recent study conducted at the Hudson Institute of Medical Research in Victoria, Australia, explored the use of EGFR-targeted nanocells in the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). The study involved 25 patients who had exhausted all other treatment options. The results showed that the nanocells provided significant overall survival (OS) and minimal side effects, with a median OS of 6.9 months for patients who completed one treatment cycle. The researchers concluded that super-cytotoxic drugs delivered via nanocells can safely treat advanced PDAC and overcome multi-drug resistance. [Extracted from the article]